Cellosign

Cellosign Overview

Cellosign has developed an application that enables efficient business processing between customer service representatives and customers. The application enables representatives to share documents interactively through real-time, bi-directional viewing and annotation of data, including eSignatures. By eliminating the barriers to digital mobile signatures, Cellosign enables call centers to increase transaction close rates while significantly reducing complexity.

Latest News

Oct 15, 2021 · www.prnewswire.com

growth-positive

CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform

CellOrigin Biotech has announced a new round of investment by Kunlun Capital for the development of its iPSC-derived innate immune cells. The company has also received investment from Shulan Health and Nest. Bio Ventures. CellOrigin Biotech focuses on iPSC-derived innate immune cells and their applications in cancer immunotherapies. They hold patents for iPSC-derived CAR-Macrophage and are collaborating with research groups worldwide. The company aims to bring more effective, universal, and safe immune cell products to cancer patients. They have initiated investigator-initiated trials at the First Hospital of Zhejiang University and have recently launched a GMP facility in Hangzhou, China. Kunlun Capital is a long-term value investor that has invested in various companies, including CellOrigin Biotech.

Investment

Funding

Team Members

3

Employees: 11-50

Web & Social Links

Locations

Abba Eban Boulevard 16, Herzliyya, Israel

Photos & Videos

1 item(s)

Cellosign Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info